In 1971, a group of researchers founded the Monash IVF Research Program with the mission to discover how in vitro fertilization, or IVF, techniques could become a treatment for infertility in both men and women. The program included researcher Carl Wood and colleagues John Leeton, Alex Lopata, Alan Trounson, and Ian Johnston at the Queen Victoria Medical Center and Royal Women’s Hospital in Melbourne, Australia. Since the program’s establishment in 1971, the Monash IVF Research Program has helped to develop and implement many IVF technologies still used in clinical practice as of 2020. Additionally, the program established some of the first successful IVF pregnancies and births. As of 2020, the Monash IVF Research Program is one of Australia’s leading fertility programs and has used their technologies to help provide IVF treatment to thousands of infertile men and women.

"MicroSort, developed in 1990 by the Genetics and IVF Institute, is a form of pre-conception sex selection technology for humans. Laboratories located around the world use MicroSort technology to help couples increase their chances of conceiving a child of their desired sex. MicroSort separates male sperm cells based on which sex chromosome they contain, which results in separated semen samples that contain a higher percentage of sperm cells that carry the same sex chromosome. The technology ultimately enables couples to choose the sex of their future child by choosing semen samples that predominately contain sperm with the X chromosome for a female or Y chromosome for a male. MicroSort technology is a sperm sorting technique that provides couples worldwide a means of pre-conception sex selection.

Ovarian hyperstimulation syndrome, abbreviated OHSS, is an atypical reaction that women may experience in response to excessive hormones, and often occurs during fertility treatments. OHSS is typically triggered by hormonal medications designed to mature eggs in the ovaries, which can cause blood vessels within the ovaries to leak fluid. Sometimes that can lead to painful tenderness or swelling. In severe cases of OHSS, that fluid can leak into the abdominal cavity in large amounts, causing vomiting, blood clots, and severe pain. As many as one out of three women undergoing fertility treatment will experience some form of OHSS, although more severe presentations are rare. While the exact cause of OHSS is not fully understood as of 2020, researchers continue to discover various risk factors, prevention techniques, and treatments that may lead to decreased risks associated with OHSS and better fertility outcomes.